PT - JOURNAL ARTICLE AU - THOMAS SELIM NAKUZ AU - ERIK BERGER AU - KAREM EL-RABADI AU - WOLFGANG WADSAK AU - ALEXANDER HAUG AU - MARCUS HACKER AU - GEORGIOS KARANIKAS TI - Clinical Value of <sup>18</sup>F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma DP - 2018 Jan 01 TA - Anticancer Research PG - 353--358 VI - 38 IP - 1 4099 - http://ar.iiarjournals.org/content/38/1/353.short 4100 - http://ar.iiarjournals.org/content/38/1/353.full SO - Anticancer Res2018 Jan 01; 38 AB - Aim: We evaluated the clinical usefulness of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine(18F-FDOPA)-positron-emission tomography (PET)/computed tomography (CT) in insulinoma detection with contrast enhancement, early acquisition time, and no carbidopa premedication. Patients and Methods: Twenty-six patients diagnosed with hyperinsulinemic hypoglycemia underwent an 18F-FDOPA PET/CT examination. Patients without carbidopa premedication and contrast-enhanced CT were included. Imaging findings were compared to the overall final diagnosis (histological findings). Results: In 10 of 26 patients (eight women, two men; mean age=53 years; age range=30-94 years), a detected lesion was confirmed histologically as an insulinoma. 18F-FDOPA PET detected the tumor in five out of ten patients. Contrast-enhanced CT also detected the tumor in five out of ten. Overall, 18F-FDOPA PET/CT, with contrast enhancement and without carbidopa premedication, was able to detect the insulinoma in seven out of ten patients (70%). Conclusion: Based on our data, 18F-DOPA PET/CT, with contrast enhancement and without carbidopa premedication, as a ‘one-stop’ diagnostic modality is a viable option for insulinoma detection.